Sarepta Therapeutics Inc (SRPT) reports a robust 39% revenue growth, achieving profitability while navigating strategic ...

As finance nerds would already know, the accrual ratio from cashflow is a key measure for assessing how well a company's free cash flow (FCF) matches its profit. The accrual ratio subtracts the FCF ...

Fintel reports that on November 7, 2024, Cantor Fitzgerald upgraded their outlook for Sarepta Therapeutics (NasdaqGS:SRPT) ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Sarepta Therapeutics (SRPT – Research Report) and DocGo (DCGO – Research Report) with bullish sentiments.

Evercore ISI analyst Gavin Clark-Gartner maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report) today and set a price ...

Sarepta Therapeutics is advancing SRP-9003 gene therapy for LGMD, with phase 3 study results expected in early 2025. Learn ...

Sarepta Therapeutics SRPT posted third-quarter 2024 adjusted earnings per share (EPS) of 62 cents, which beat the Zacks Consensus Estimate of a loss of 15 cents. Earnings rose 99% year over year, ...

Investors in Sarepta Therapeutics Inc (Symbol: SRPT) saw new options begin trading today, for the December 13th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down ...

Fintel reports that on November 7, 2024, Cantor Fitzgerald upgraded their outlook for Sarepta Therapeutics (NasdaqGS:SRPT) from Neutral to Overweight. As of October 22, 2024, the average one-year ...